Aciloc RD consists of Domperidone 20 mg, Omeprazole 10 mg. Aciloc prevents the tendency of vomiting and nausea in people suffering from gastrointestinal problems.
Omeprazole belongs to the category of antacid/ anti-ulcerant called PPI. It exhibits action by blocking the H1 receptor in the stomach cells leading to reducing the quantum of acid produced. Domperidone is an antiemetic (against vomiting) agent which acts by preventing the vomiting by action on the specific vomiting centre in the brain. It is also known to induce normalization of gastric motility (peristalsis). Aciloc- RD scores over conventional antacids in better control of hyper acidity.
Aciloc RD is a product marketed by Cadila Pharmaceuticals. Cadila Pharmaceuticals Limited, established in 1951 is one of the largest privately held pharmaceuticals companies in India. It is an innovation and research focused company, which has been developing, manufacturing, selling and distributing pharmaceutical products across more than 45 therapeutic areas.
You have been prescribed Aciloc- RD as you may be suffering from Dypepsia or GERD.
Stomach disorders are the most common cause of doctor visits. Faulty eating habits, irregular meal timings, less sleep or faulty oesophageal sphincter. Most commonly found condition is called dyspepsia (indigestion).
Dyspepsia: This is caused due to excess amount of undigested food which causes heartburn, burps, bloating / flatulence etc. General feeling of discomfort is present in the patient which can be eased by antacids, digestive enzymes and having light food.
GERD : Also known as Gastro oesophageal reflux disease ,it is caused by the faulty lower mechanism of the valve between oesophagus and stomach known as lower oesophageal sphincter. This causes the stomach contents to travel back into oesophagus leading to heartburn as the major symptom apart from vomiting sensation. GERD is usually treated with antacid / anti emetic agents which help relieve symptoms.
Gastric endoscopy is normally used to diagnose the condition of GERD.
As directed by your physician.
As directed by your physician.
Adverse Reactions/ Side Effects
Domperidone: Dry mouth, transient skin rash, itching, headache, diarrhoea and rarely nervousness. Omeprazole: Anaemia, eosinopaenia, urinary tract infection, skin rash, urticaria and pruritus, diarrhoea, headache, constipation, nausea, vomiting, flatulence and abdominal pain, dizziness and lightheadedness, somnolence, insomnia and vertigo, reversible confusion, agitation, depression and hallucinations, arthritic and myalgic symptoms
Warnings and Precautions
Domperidone can cause a rise in serum prolactin level resulting in galactorrhoea in females and less frequently gynaecomastia in males. Hypertensive crisis may occur in patients with phaeochromocytoma. Renal impairment or those at risk of fluid retention. Hepatic impairment; elderly. Exclude the possibility of malignancy if gastric ulcer is suspected, before initiating treatment with omeprazole, it may mask symptoms and delay diagnosis. Monitor patients on warfarin or phenytoin therapy, reduce dose if necessary
Pregnancy. Domperidone is contraindicated in conditions associated with rise in prolactin level. Omeprazole is contraindicated in hypersensitive patients
Anticholinergics may antagonize beneficial effects of domperidone in reflux oesophagitis and dyspepsia. Decreased bioavailability of domperidone after prior admin of cimetidine or Na bicarbonate. Delayed elimination of diazepam, phenytoin and warfarin with omeprazole
Mechanism of Action
Domperidone is a peripheral dopamine D2-receptor antagonist, which regulates the motility of gastric and small intestinal smooth muscle. It increases the duration of antral and duodenal contractions and also LES resting pressure, thus stimulating gastric emptying and is also effective in relief of symptoms of reflux esophagitis. Antiemetic activity is due to the blockade of dopamine receptors in the chemoreceptor trigger zone.
Omeprazole inhibits the secretion of gastric acid by irreversibly blocking the enzyme system of H+/K+ ATPase of the gastric parietal cell. It is activated at an acidic pH to a sulphenamide derivative that binds irreversibly to H+/K+ ATPase, an enzyme system found at the secretory surface of parietal cells. It thereby inhibits the final transport of hydrogen ions (via exchange with K ions) into the gastric lumen